Filing Flows › Pharma-Bio Serv (PBSV) › Q3 FY25
Pharma-Bio Serv (PBSV) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Sep 15, 2025
Pharma-Bio Serv (PBSV) reported revenue of $2.0M for the third quarter fiscal 2025 (Q3 FY25), -19% from a year earlier and -19% from the quarter before. Operating margin was -16.0%, net loss $204K (10.4% of revenue).
Pharma-Bio Serv, Q3 FY25: revenue $2.0M (-19% year over year), operating margin -16.0%, net loss $204K, operating cash flow $237K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | -19% | -19% |
| Operating profit | −$314K | — | — |
| Net earnings | −$204K | -314% | — |
| Operating cash flow | $237K | — | — |
| Free cash flow | $234K | — | — |
What changed
Revenue was $2.0M in Q3 FY25, down 19% year over year and down 19% from the previous quarter.
Gross margin was 29.3%, up 3.0 points from a year earlier. Operating costs exceeded revenue by $314K, an operating margin of -16.0%. Operating expenses fell 13% while revenue fell 19%. The quarter ended with a net loss of $204K, after a profit of $95K the previous quarter. Non-operating items added $114K, -57% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $237K. Non-cash charges added back $16K of depreciation and amortization and $10K of share-based compensation. Working capital and other items added $415K. Capital expenditures of $2K left free cash flow of $234K.
Questions
What was Pharma-Bio Serv's revenue in the third quarter fiscal 2025?
Pharma-Bio Serv (PBSV) reported revenue of $2.0M for the third quarter fiscal 2025 (Q3 FY25), -19% from a year earlier and -19% from the quarter before.
Was Pharma-Bio Serv profitable in the third quarter fiscal 2025?
Operating loss was $314K (-16.0% of revenue) and net loss $204K.
Source: Pharma-Bio Serv 10-Q on SEC EDGAR.